Labaran Waya

An yi wa majiyyaci na farko allura don samun ci gaba mai ƙarfi

Written by edita

Jubilant Therapeutics Inc. a yau ya sanar da adadin majiyyaci na farko a cikin gwaji na asibiti na Phase I/II na JBI-802 a cikin marasa lafiya da ciwace-ciwacen ciwace-ciwace. JBI-802 shine na farko-a-aji, ƙananan ƙwayoyin cuta, mai hana dual inhibitor na LSD1 da HDAC6 wanda ya nuna aikin anti-tumor synergistic a cikin ƙirar dabba.  

Gwajin gwaji na Mataki na I / II shine alamar budewa, haɓaka kashi biyu na haɓakawa da haɓakar haɓakawa da aka tsara don ayyana aminci da haƙuri, bincika masu ƙididdigewa da tantance ayyukan farko na JBI-802 a cikin mahalarta binciken fiye da 100 tare da ci gaba mai ƙarfi. Ana iya samun ƙarin bayani game da gwajin asibiti a NCT05268666.

Hari S Bhartia, Shugaban, Jubilant Therapeutics Inc. ya raba kan sanarwar, “Mun yi nisa daga gano muggan ƙwayoyi zuwa alluran farko a cikin ɗan adam. Muna sa ran kawo canji a rayuwar marasa lafiya. Kwarewarmu a cikin ƙirar magungunan da ta dogara da tsarin da kuma sinadarai na magani suna ba mu damar ƙirƙirar bambance-bambancen madaidaicin hanyoyin warkewa tare da ingantaccen kaddarorin gaske."

Syed Kazmi, Babban Jami'in Gudanarwa, Jubilant Therapeutics Inc. ya ce, "JBI-802, yana daidaita daidaitattun ingantattun makasudin oncology guda biyu tare da alaƙa iri ɗaya da saurin kashewa / kashe motsin motsa jiki, wanda ke haifar da ayyukan rigakafin kumburi tare da rage haɗarin thrombocytopenia. Wannan shine ɗan takarar samfurin mu na farko da aka haɓaka don shiga haɓakar asibiti. Sauran shirye-shiryen ci gaba sun haɗa da mai hana mai shiga kwakwalwa ta baki na PRMT5, JBI 778, da mai hana PDL1 mai hana kwakwalwar baka, JBI 2174, don ciwon daji na jijiyoyin jini da sauransu."

Babu alamun wannan post.

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...